1. Home
  2. PBFS vs IMMP Comparison

PBFS vs IMMP Comparison

Compare PBFS & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pioneer Bancorp Inc.

PBFS

Pioneer Bancorp Inc.

N/A

Current Price

$13.67

Market Cap

333.8M

Sector

Finance

ML Signal

N/A

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.40

Market Cap

410.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PBFS
IMMP
Founded
1889
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
333.8M
410.7M
IPO Year
2019
2012

Fundamental Metrics

Financial Performance
Metric
PBFS
IMMP
Price
$13.67
$0.40
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$5.50
AVG Volume (30 Days)
8.4K
2.5M
Earning Date
04-30-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
36.07
N/A
EPS
0.83
N/A
Revenue
$15,814,000.00
N/A
Revenue This Year
N/A
$382.75
Revenue Next Year
N/A
N/A
P/E Ratio
$16.39
N/A
Revenue Growth
5.76
N/A
52 Week Low
$10.60
$0.40
52 Week High
$15.18
$3.53

Technical Indicators

Market Signals
Indicator
PBFS
IMMP
Relative Strength Index (RSI) 41.45 13.19
Support Level $12.89 N/A
Resistance Level $14.08 $1.90
Average True Range (ATR) 0.33 0.12
MACD -0.09 -0.27
Stochastic Oscillator 14.29 0.24

Price Performance

Historical Comparison
PBFS
IMMP

About PBFS Pioneer Bancorp Inc.

Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: